Biogen to buy DFW rare disease firm for $7.2B


Biogen is paying $7.2 billion to buy a DFW biotech as the new CEO makes good on his promise to expand into the rare disease space.

Previous T. Rowe Price CEO: $20B in client outflows 'clearly the missing ingredient'
Next Chef Peter Merriman expands Monkeypod Kitchen to Waikiki